Takeda Pharmaceuticals

Free Case Evaluation

Takeda Pharmaceuticals is a subsidiary company of Takeda Pharmaceuticals Company Limited. They are the largest drug company in Japan. Takeda Pharmaceuticals was founded in 1998, and they are ranked as one of the top pharmaceutical companies of the U.S. A substantial amount of their success has come from their drug for treating type 2 diabetes, Actos.

The company was originally founded in Osaka, Japan in 1781. Takeda began importing pharmaceutical supplies from the west in 1871. Takeda Pharmaceuticals was known as a cooperative union at the time. They were known as Chobei Takeda & Company Limited in 1925 and the company was worth approximately $1 million at the time.

During World War II Takeda Pharmaceuticals supplied penicillin and B vitamins. Shortly after World War II, the company began trading stock internationally. Takeda Pharmaceuticals had consistent growth at about 20 percent a year. Takeda Pharmaceuticals expanded both their U.S. and European markets in 1985 when they started marketing their anti-cancer medication, Lupron Depot.

Problems From Actos

Takeda Pharmaceuticals’ type 2 diabetes medication, Actos, was approved by the FDA in 1999. Actos is a thiazolidinedione, or TZD, compound similar to other type 2 diabetes medications. Actos has been prescribed to over 10 million type 2 diabetes patients around the world. This has made Actos one of the most popular drugs for treating type 2 diabetes.

At the time, it was lauded as a better choice than the other leading type 2 diabetes medication at the time, Avandia. Actos had the advantage of not needing to carefully monitor patients for heart problems from the drug. However, this issue still became a problem for Takeda Pharmaceuticals after several hundred patients had developed serious health problems from Actos treatment.

In 2011, a study was released that claimed Actos increased the risk of bladder cancer by as much as 40 percent. The study also showed that the risk was more substantial for patients that were prescribed for longer than a year. Another study was published claiming that the risk can be as high as 83 percent. Furthermore, other health conditions from Actos were also discovered. Lactic acidosis, bone fracture, and macular edema were all linked to Actos usage.

In 2007, the FDA issued a “black box warning,” or “black label warning,” because of studies that had shown congestive heart failure as an increased risk from Actos treatment. Despite the warning, Actos became the most widely prescribed drug for treating type 2 diabetes. Part of this was because another popular diabetes medication, Avandia, was taken off the U.S. Market.

Takeda Pharmaceuticals Lawsuits

Takeda Pharmaceuticals was the focus of several lawsuits regarding their type 2 diabetes medication, Actos. Patients that were prescribed to Actos began experiencing adverse reactions as a result of the side effects from Actos.

Among these problems were congestive heart failure and bladder cancer. Bladder cancer became the leading reason for lawsuits filed against Takeda Pharmaceuticals. There were over 10,000 lawsuits filed against Takeda Pharmaceuticals over bladder cancer in Actos patients. Congestive heart failure is another potentially-fatal condition that affects Actos patients as well. Congestive heart failure is another one of the main reasons for filing suit against Takeda Pharmaceuticals.

Takeda Pharmaceuticals was accused of hiding information regarding Actos. A safety consultant from the FDA filed suit against Takeda Pharmaceuticals because of bad reactions that were not being reported to necessary officials. The report states that there were many reports of delirium and suicide along with other reports of bladder cancer and congestive heart failure.

Takeda Pharmaceuticals is facing a large number of lawsuits from Actos. Many of the charges against Takeda Pharmaceuticals have been filed as a multidistrict litigation (MDL). This is when several federal lawsuits become grouped into one court case in order to simplify the judicial process. There are also several state court lawsuits from the use of Actos for type 2 diabetes.

View Sources

  1. Feeley, Jef. “Takeda May Face 10,000 U.S. Suits Over Actos Cancer Claims.” Bloomberg. N.p., 06 Dec 2011. Web. 30 Apr 2013. http://www.businessweek.com/news/2011-12-06/takeda-may-face-10-000-u-s-suits-over-actos-cancer-claims.html
  2. Matsuyama, Kanoko. “Takeda’s Diabetes Drug Alogliptin Rejected by FDA (Update1).” Bloomberg. N.p., 27 Jun 2009. Web. 30 Apr 2013. http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aphMYQhqhmNI
  3. Matsuyama, Kanoko. “Takeda Pays ‘Upper Limit’ for Nycomed as Competition Looms for Actos Pill.”Bloomberg. N.p., 20 May 2011. Web. 30 Apr 2013. http://www.bloomberg.com/news/2011-05-19/takeda-pays-upper-limit-for-nycomed-in-growth-bid.html
Have you been affected by a drug or device listed? Call 1-888-537-3057